• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

BUILDING A CASE TO SUE IMS

Anonymous

Guest
I work in SW Arkansas and SW Missouri. Alot of rural areas in my geography. I have proof of prescriptions being written and not being captured. I have enough info to this point to hold IMS accountable for their methodologies. I am working with a lawyer to find out how we move forward in the case. I think it is finally time to hold your company accountable and the stress and anxiety of inaccurate sales numbers.
 




Save your money. You stand a better chance (still right next to nothing) of suing your company for buying a faulty product and tying their entire compensation system to it. IMS doesn't put a gun to anyone's head and tell them to 'buy this' or they will shoot. They disclose that their methodology is 'projected'. Pharma is just too lazy and/or stupid to do anything about it.

Before I am accused of being an IMS shill I want to state that I personally believe that the physician level data is pretty weak. There are too many holes in it to accurately gauge individual doctor Rxing and therefore rep performance. But in the land of the blind, the one-eyed man is king. And in the land of the lazy, pharma companies refuse to base compensation on something other than canned, kind-of-good-enough data.

My advice is to pick another windmill to attack but it's your dime.